No indication of insulin resistance in idiopathic PAH with preserved physical activity
- Bence M. Nagy1,
- Gabor Kovacs1,2,
- Adrienn Tornyos1,3,
- Eva Svehlikova4,
- Vasile Foris1,2,
- Chandran Nagaraj1,
- Grazyna Kwapiszewska1,5,
- Thomas R. Pieber4,
- Andrea Olschewski1,6 and
- Horst Olschewski1,2
- 1Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria
- 2Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
- 3Division of General Radiology, Department of Radiology, Medical University of Graz, Graz, Austria
- 4Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
- 5Otto Loewi Center, Medical University of Graz, Graz, Austria
- 6Division of Special Anaesthesiology, Pain and Intensive Care Medicine, Department of Anaesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria
- Mr Bence M. Nagy. E-mail: bence.nagy{at}lvr.lbg.ac.at
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Nagy has nothing to disclose.
Conflict of interest: Dr. Kovacs reports personal fees and non-financial support from Actelion, personal fees and non-financial support from Bayer, personal fees and non-financial support from GSK, personal fees and non-financial support from MSD, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Novartis, personal fees and non-financial support from Chiesi, non-financial support from VitalAire, non-financial support from AOP, outside the submitted work.
Conflict of interest: Dr. Tornyos has nothing to disclose.
Conflict of interest: Dr. Svehlikova has nothing to disclose.
Conflict of interest: Dr. Foris reports non-financial support from Actelion, non-financial support from AstraZeneca, personal fees from Bayer, personal fees and non-financial support from Boehringer Ingelheim, personal fees from GSK, personal fees and non-financial support from MSD, non-financial support from Novartis, non-financial support from BMS, personal fees from Gerrot Lannach, non-financial support from Chiesi, outside the submitted work.
Conflict of interest: Dr. Nagaraj has nothing to disclose.
Conflict of interest: Dr. Kwapiszewska has nothing to disclose.
Conflict of interest: Dr. Pieber has nothing to disclose.
Conflict of interest: Dr. Olschewski has nothing to disclose.
Conflict of interest: Dr. Olschewski reports personal fees and non-financial support from Bayer, grants, personal fees and non-financial support from Actelion, personal fees and non-financial support from MSD, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Novartis, grants from Inventiva, personal fees from Bellerophon, outside the submitted work; and Horst Olschewski is part time employee of Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received July 11, 2019.
- Accepted February 15, 2020.
- Copyright ©ERS 2020